Resource Summary Report

Generated by FDI Lab - SciCrunch.org on Apr 15, 2025

VCaP

RRID:CVCL_2235
Type: Cell Line

Proper Citation

(RRID:CVCL_2235)

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_2235

Proper Citation: (RRID:CVCL_2235)

Sex: Male

Defining Citation: PMID:11317522, PMID:14518029, PMID:14518030, PMID:21698104, PMID:22460905, PMID:23447416, PMID:23615946, PMID:23671654, PMID:25877200, PMID:25984343, PMID:27397505, PMID:28145883, PMID:29194687, PMID:30244336, PMID:30305041, PMID:30894373, PMID:31068700, PMID:31395879, PMID:31978347, PMID:34402095, PMID:35839778, PMID:38892296

Comments: Omics: Transcriptome analysis by RNAseq., Omics: Transcriptome analysis by microarray., Omics: SNP array analysis., Omics: shRNA library screening., Omics: DNA methylation analysis., Omics: Deep quantitative proteome analysis., Omics: Deep exome analysis., Virology: Contains an integrated xenotropic MuLV-related virus (XMRV) Bxv-1 (PubMed=21698104)., Characteristics: Established from a xenograft produced by implantation of tumor cells in a SCID mouse., Population: Caucasian., Part of: TCGA-110-CL cell line panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Name: VCaP

Synonyms: VCAP, Vcap, Vertebral Cancer of the Prostate

Cross References: BTO:BTO_0003215, CLO:CLO_0037117, EFO:EFO_0007752, AddexBio:C0019001/73, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ATCC:CRL-2876, BioSample:SAMN03473238, BioSample:SAMN05292448,

BioSample:SAMN10988209, cancercelllines:CVCL_2235, CCRID:3101HUMSCSP5034, CCRID:3101HUMTCHu220, Cell_Model_Passport:SIDM01077, ChEMBL-Cells:CHEMBL4295435, ChEMBL-Targets:CHEMBL4296508, CLS:300631, Cosmic:1028646, Cosmic:1028698, Cosmic:1043330, Cosmic:1071482, Cosmic:1689710, Cosmic:1995663, Cosmic:2580131, Cosmic-CLP:1299075, DepMap:ACH-000115, ECACC:06020201, EGA:EGAS00001000978, ENCODE:ENCBS316RCQ, ENCODE:ENCBS626UQL, GDSC:1299075, GEO:GSM525805, GEO:GSM648824, GEO:GSM887731, GEO:GSM888826, GEO:GSM1374984, GEO:GSM1440913, GEO:GSM1440914, GEO:GSM1633311, GEO:GSM1633312, GEO:GSM1633313, GEO:GSM1670571, GEO:GSM2069530, GEO:GSM2069531, GEO:GSM2069532, GEO:GSM2069533, GEO:GSM2069534, GEO:GSM2069535, GEO:GSM2069536, GEO:GSM2069537, GEO:GSM3145745, GEO:GSM3407124, GEO:GSM3407125, GEO:GSM3407126, GEO:GSM3407127, GEO:GSM3407128, GEO:GSM3407129, GEO:GSM5402196, IARC_TP53:18891, IZSLER:BS TCL 234, LiGeA:CCLE_269, LINCS_LDP:LCL-1147, PharmacoDB:VCaP_1653_2019, PRIDE:PXD030304, Progenetix:CVCL_2235, PubChem_Cell_line:CVCL_2235, Wikidata:Q29511246

ID: CVCL_2235

Record Creation Time: 20250131T203052+0000

Record Last Update: 20250131T205119+0000

Ratings and Alerts

No rating or validation information has been found for VCaP.

No alerts have been found for VCaP.

Data and Source Information

Source: Cellosaurus

Usage and Citation Metrics

We found 231 mentions in open access literature.

Listed below are recent publications. The full list is available at FDI Lab - SciCrunch.org.

Huttunen J, et al. (2024) EP300/CREBBP acetyltransferase inhibition limits steroid receptor and FOXA1 signaling in prostate cancer cells. Cellular and molecular life sciences : CMLS, 81(1), 160.

Graham K, et al. (2024) Discovery of YAP1/TAZ pathway inhibitors through phenotypic screening with potent anti-tumor activity via blockade of Rho-GTPase signaling. Cell chemical biology, 31(7), 1247.

Paniagua-Herranz L, et al. (2024) Genomic and Immunologic Correlates in Prostate Cancer with High Expression of KLK2. International journal of molecular sciences, 25(4).

Walker L, et al. (2024) Defining Splicing Factor Requirements for Androgen Receptor Variant Synthesis in Advanced Prostate Cancer. Molecular cancer research : MCR, 22(12), 1128.

Iyer RF, et al. (2024) CD8+ T cell targeting of tumor antigens presented by HLA-E. Science advances, 10(19), eadm7515.

Yoshida S, et al. (2024) TAS3681, an androgen receptor antagonist, prevents drug resistance driven by aberrant androgen receptor signaling in prostate cancer. Molecular oncology, 18(8), 1980.

Vellky JE, et al. (2024) ERBB3 Overexpression is Enriched in Diverse Patient Populations with Castration-sensitive Prostate Cancer and is Associated with a Unique AR Activity Signature. Clinical cancer research : an official journal of the American Association for Cancer Research, 30(8), 1530.

Calì B, et al. (2024) Coagulation factor X promotes resistance to androgen-deprivation therapy in prostate cancer. Cancer cell, 42(10), 1676.

Gulliver C, et al. (2024) cAMP-phosphodiesterase 4D7 (PDE4D7) forms a cAMP signalosome complex with DHX9 and is implicated in prostate cancer progression. Molecular oncology, 18(3), 707.

Manzar N, et al. (2024) An integrative proteomics approach identifies tyrosine kinase KIT as a therapeutic target for SPINK1-positive prostate cancer. iScience, 27(3), 108794.

Sugawara T, et al. (2024) Dual targeting of the androgen receptor and PI3K/AKT/mTOR pathways in prostate cancer models improves antitumor efficacy and promotes cell apoptosis. Molecular oncology, 18(3), 726.

Sen A, et al. (2024) Assessments of prostate cancer cell functions highlight differences between a pan-PI3K/mTOR inhibitor, gedatolisib, and single-node inhibitors of the PI3K/AKT/mTOR pathway. Molecular oncology.

Goradia N, et al. (2024) Master corepressor inactivation through multivalent SLiM-induced polymerization mediated by the oncogene suppressor RAI2. Nature communications, 15(1), 5241.

Beatson EL, et al. (2024) Genomic Characterization of Preclinical Prostate Cancer Cell Line Models. International journal of molecular sciences, 25(11).

Xiong Z, et al. (2024) Cancer-associated fibroblasts promote enzalutamide resistance and

PD-L1 expression in prostate cancer through CCL5-CCR5 paracrine axis. iScience, 27(5), 109674.

Gui F, et al. (2024) Acute BRCAness Induction and AR Signaling Blockage through CDK12/7/9 Degradation Enhances PARP Inhibitor Sensitivity in Prostate Cancer. bioRxiv : the preprint server for biology.

Poluben L, et al. (2024) Increased nuclear factor I-mediated chromatin access drives transition to androgen receptor splice variant dependence in prostate cancer. Cell reports, 44(1), 115089.

Afshan S, et al. (2024) Targeting the cancer cells and cancer-associated fibroblasts with next-generation FGFR inhibitors in prostate cancer co-culture models. Cancer medicine, 13(18), e70240.

Jeon HY, et al. (2023) SMAD3 promotes expression and activity of the androgen receptor in prostate cancer. Nucleic acids research, 51(6), 2655.

Yu X, et al. (2023) Inhibition of castration-resistant prostate cancer growth by genistein through suppression of AKR1C3. Food & nutrition research, 67.